info@p-95.com

Clinical Trial Delivery

Comprehensive Clinical Trial Support for Vaccines and Infectious Disease.

Data, Analysis and writing

Our data management, biostatistics, safety management and medical writing teams ensure data integrity and insightful analysis for vaccines and drugs across all stages of development.

Epidemiology and Real-World Evidence (RWE) Solutions

Comprehensive Epidemiology and RWE solutions for Vaccines and Infectious Diseases.

Africa and LMICs

Expanding Clinical and Epidemiological Horizons: Expertise in Africa, LMICs, and Beyond.

VIEW ALL SERVICES

Vaccination Programmes | Epidemiology, Monitoring, Evaluation book now available open access

Our P95 colleague Kaatje Bollaerts is excited to announce that the book ‘Vaccination Programmes | Epidemiology, Monitoring, Evaluation’ by Susan Hahné, Kaatje Bollaerts, and Paddy Farrington is now available to all to view and use online through a new open-access grant provided by CEPI.

Aimed at those involved, or planning to be involved, in many aspects of vaccination programmes, including public health professionals and epidemiologists, the book explores epidemiologic methods that can be used to study, in real life, their impacts, benefits, and risks.

Please feel free to download the book or read the book online through this link: https://lnkd.in/dAh65S2A

P95

Pioneering Clinical Excellence in Vaccines and Infectious Diseases

Tags:

0 Comments

You May Also Like

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).

Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.